94. Primary sclerosing cholangitis
134 clinical trials,   105 drugs   (DrugBank: 37 drugs),   18 drug target genes,   131 drug target pathways

Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04595825
(ClinicalTrials.gov)
October 1, 20207/10/2020CM-101 in PSC Patients -The SPRING StudyA Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating The Safety And Efficacy Of CM-101 In Subjects With Primary Sclerosing Cholangitis- The SPRING StudyPrimary Sclerosing CholangitisBiological: CM-101;Other: PlaceboChemomAb Ltd.NULLRecruiting18 Years75 YearsAll45Phase 2Israel;United Kingdom
2EUCTR2019-002945-39-GB
(EUCTR)
15/04/202014/11/2019A study to look at how well study drug CM-101 works in people with disease of the liver and gallbladder characterized by inflammation and scarring of the bile ductsA Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects with Primary Sclerosing Cholangitis - The SPRING study Primary Sclerosing Cholangitis
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: CM-101
Product Code: CM-101
INN or Proposed INN: TBC
Other descriptive name: Humanised IgG1 monoclonal antibody against human eotaxin-2
ChemomAb LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
45Phase 2Israel;United Kingdom
3EUCTR2018-004258-77-GB
(EUCTR)
05/02/201926/11/2018A phase 2 study being run in multiple centres to evaluate the safety, tolerability and efficacy of a study drug (called CM-101) which will be given to patients with primary sclerosing cholangitis for 12 weeks.A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis. - The SPRING Study Treatment of Primary Sclerosing Cholangitis
MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
ChemomAb Ltd.NULLNot Recruiting Female: yes
Male: yes
30Phase 2Israel;United Kingdom